Walker Karen
Known title: DirectorCIK: 0001642519
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Transaction History
| SPT | ▲ Buy | Grant | 26,470 | $0 | 5/20/2026 | View on chart |
| SPT | ▼ Sell | Open Market | 5,000 | $95K | 7/14/2025 | View on chart |
| SPT | ▲ Buy | Grant | 8,298 | $0 | 5/22/2025 | View on chart |
| SPT | ▼ Sell | Open Market | 5,000 | $97K | 4/14/2025 | View on chart |
| SPT | ▼ Sell | Open Market | 5,000 | $151K | 1/13/2025 | View on chart |
| SPT | ▼ Sell | Open Market | 4,700 | $161K | 12/13/2024 | View on chart |
| SPT | ▼ Sell | Open Market | 300 | $11K | 12/13/2024 | View on chart |
| LLY | ▲ Buy | Grant | 303 | $220K | 11/18/2024 | View on chart |
| SPT | ▼ Sell | Open Market | 3,500 | $109K | 8/7/2024 | View on chart |
| SPT | ▲ Buy | Grant | 5,612 | $0 | 5/22/2024 | View on chart |
| SPT | ▼ Sell | Open Market | 3,500 | $225K | 3/4/2024 | View on chart |
| LLY | ▲ Buy | Grant | 335 | $200K | 11/20/2023 | View on chart |
| SPT | ▼ Sell | Open Market | 4,000 | $212K | 9/1/2023 | View on chart |
| SPT | ▼ Sell | Open Market | 986 | $44K | 8/9/2023 | View on chart |
| SPT | ▼ Sell | Open Market | 986 | $44K | 8/9/2023 | View on chart |
| SPT | ▼ Sell | Open Market | 987 | $44K | 8/9/2023 | View on chart |
| SPT | ▲ Buy | Grant | 3,895 | $0 | 5/22/2023 | View on chart |
| SPT | ▼ Sell | Open Market | 2,100 | $136K | 3/8/2023 | View on chart |
| SPT | ▼ Sell | Open Market | 5,900 | $375K | 3/8/2023 | View on chart |
| SPT | ▼ Sell | Open Market | 6,000 | $387K | 3/8/2023 | View on chart |
| LLY | ▲ Buy | Grant | 498 | $180K | 11/21/2022 | View on chart |
| SPT | ▼ Sell | Open Market | 3,800 | $230K | 11/18/2022 | View on chart |
| SPT | ▼ Sell | Open Market | 1,200 | $73K | 11/18/2022 | View on chart |
| SPT | ▼ Sell | Open Market | 3,987 | $247K | 11/17/2022 | View on chart |
| SPT | ▼ Sell | Open Market | 3,987 | $247K | 11/17/2022 | View on chart |
| SPT | ▼ Sell | Open Market | 3,987 | $247K | 11/17/2022 | View on chart |
| SPT | ▼ Sell | Open Market | 400 | $24K | 8/30/2022 | View on chart |
| SPT | ▼ Sell | Open Market | 8,500 | $502K | 8/29/2022 | View on chart |
| SPT | ▲ Buy | Grant | 4,164 | $0 | 5/25/2022 | View on chart |
| LLY | ▲ Buy | Grant | 677 | $175K | 11/15/2021 | View on chart |
| SPT | ▼ Sell | Open Market | 4,750 | $628K | 11/8/2021 | View on chart |
| SPT | ▼ Sell | Open Market | 10,250 | $1.3M | 11/8/2021 | View on chart |
| SPT | ▼ Sell | Gift | 7,974 | $0 | 10/5/2021 | View on chart |
| SPT | ▼ Sell | Gift | 7,973 | $0 | 10/5/2021 | View on chart |
| SPT | ▼ Sell | Gift | 23,920 | $0 | 10/5/2021 | View on chart |
| SPT | ▼ Sell | Gift | 7,973 | $0 | 10/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Sprout Social shares fall amid AI governance and risk concerns
Recent Yahoo articles note that Sprout Social’s stock has dropped sharply along with other software names. The decline is linked to heightened scrutiny of AI governance spending and the classification of the company as a risky small‑cap. These factors may pressure the share price, which is currently near its support level. Analysts’ average target remains well above the current price.
Sprout Social shares fall amid AI governance and risk concerns. Recent Yahoo articles note that Sprout Social’s stock has dropped sharply along with other software names. The decline is linked to heightened scrutiny of AI governance spending and the classification of the company as a risky small‑cap. These factors may pressure the share price, which is currently near its support level. Analysts’ average target remains well above the current price.